CoChat
Sign Up
Cited by 477Pharmaceutical Economics and PolicyHealth and Medical Research ImpactsGlobal Health Care Issues

The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.

Mapping of available health research and development data: what's there, what's missing, and what role is there for a global observatory?

Røttingen, John-Arne, Regmi, Sadie, Eide, Mari, Young, Alison J, Viergever, Roderik F, Årdal, Christine, Guzman, Javier, Edwards, Danny, Matlin, Stephen A, Terry, Robert F·2013·The Lancet
DOI 10.1016/s0140-6736(13)61046-6
Open this paper in CoChat — free account

Abstract

The need to align investments in health research and development (R&D) with public health demands is one of the most pressing global public health challenges. We aim to provide a comprehensive description of available data sources, propose a set of indicators for monitoring the global landscape of health R&D, and present a sample of country indicators on research inputs (investments), processes (clinical trials), and outputs (publications), based on data from international databases. Total global investments in health R&D (both public and private sector) in 2009 reached US$240 billion. Of the US$214 billion invested in high-income countries, 60% of health R&D investments came from the business sector, 30% from the public sector, and about 10% from other sources (including private non-profit organisations). Only about 1% of all health R&D investments were allocated to neglected diseases in 2010. Diseases of relevance to high-income countries were investigated in clinical trials seven-to-eight-times more often than were diseases whose burden lies mainly in low-income and middle-income countries. This report confirms that substantial gaps in the global landscape of health R&D remain, especially for and in low-income and middle-income countries. Too few investments are targeted towards the health needs of these countries. Better data are needed to improve priority setting and coordination for health R&D, ultimately to ensure that resources are allocated to diseases and regions where they are needed the most. The establishment of a global observatory on health R&D, which is being discussed at WHO, could address the absence of a comprehensive and sustainable mechanism for regular global monitoring of health R&D.

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(13)61046-6

Cites

21 of 21 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 21 references

Cited by

Sorted by citations

See all 477

Related

See all

Metadata

Authors
Røttingen, J.-A., Regmi, S., Eide, M., Young, A. J., Viergever, R. F., Årdal, C., Guzman, J., Edwards, D., Matlin, S. A., & Terry, R. F.
Affiliations
  • Harvard University (US)
  • University of Manchester (GB)
  • Norwegian University of Science and Technology (NO)
  • Organisation de Coopération et de Développement Economiques (FR)
  • Radboud University Nijmegen (NL)
  • University of Oslo (NO)
  • Council on Health Research for Development (CH)
  • Imperial College London (GB)
  • World Health Organization (CH)
ORCID
Venue
The Lancet
Publisher
Elsevier BV
Published
2013-10
Volume
382
Issue
9900
Pages
1286-1307
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
DOI
10.1016/s0140-6736(13)61046-6
OpenAlex
W2025776410
Cited by
477
References
21
Citations by year
2026: 14 · 2025: 19 · 2024: 21 · 2023: 10 · 2022: 16 · 2021: 61 · 2020: 25 · 2019: 23 · 2018: 26 · 2017: 169 · 2016: 33 · 2015: 26 · 2014: 22 · 2013: 10
FWCI
71.21
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Global Health Care Issues
Keywords
health research and development, clinical trials, research output, neglected diseases, low- and middle-income countries, priority setting, data gaps
MeSH terms
Clinical Trials as Topic, Data Collection, Developing Countries, Humans, Public Health, Publishing, Research Support as Topic, Global Health, Developed Countries, Databases as Topic, Needs Assessment, Information Dissemination, Biomedical Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review